AI-powered device to identify low LV ejection fraction gains FDA 510(k) clearance

Related Articles
Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm
DAIC: Anumana, Inc., a leading AI-driven health technology company, has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its ECG-AI algorithm designed to aid the…June 21, 2023
Uncertainty Estimation in Healthcare AI
Building on our previous discussion of imbalanced regression, we now turn to another critical challenge: uncertainty estimation. While addressing data imbalance helps models pay attention to rare cases, we must also…September 05, 2025
Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm
Developed in collaboration with Mayo Clinic, with support from Pfizer, this ECG-AI algorithm aims to aid physicians in earlier identification of cardiac amyloidosisJune 21, 2023
Anumana & Pfizer Partner on Amyloidosis AI-ECG Algorithm Development
HIT Consultant: Anumana, an AI-driven health technology company and portfolio company of nference, today announced a multi-year agreement with Pfizer for Anumana to develop an investigational artificial intelligence electrocardiogram algorithm…December 16, 2022


